SHR-8068；Adebrelimab ；Bevacizumab
Preclinical
Suzhou Suncadia Biopharmaceuticals Co., Ltd.SHR-8068；Adebrelimab ；Bevacizumab is one of 6 therapeutic programs targeting Advanced Renal Cell Carcinoma. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
5
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
6 competitors in Advanced Renal Cell Carcinoma
#DrugCompanyPhaseTrials
1Cabometyx
Bristol-Myers SquibbPhase 2
Cometriq
EExelixis
Phase 2
Keytruda
Merck & Co.Phase 1
Januvia
ZZydus Therapeutics Inc.
Phase 1
Shr-8068；adebrelimab
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Preclinical
SHR-8068；Adebrelimab ；Bevacizumab
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Preclinical[1]